{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T16:06:33Z","timestamp":1750262793223},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00108-022-01386-w","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T11:18:11Z","timestamp":1659439091000},"page":"947-960","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["ANCA-assoziierte Vaskulitis"],"prefix":"10.1007","volume":"63","author":[{"given":"Marco L.","family":"Krasselt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia U.","family":"Holle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"1386_CR1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","volume":"98","author":"AS Fauci","year":"1983","unstructured":"Fauci\u00a0AS, Haynes\u00a0BF, Katz\u00a0P et\u00a0al (1983) Wegener\u2019s granulomatosis: prospective clinical and therapeutic experience with 85\u00a0patients for 21\u00a0years. Ann Intern Med 98:76\u201385","journal-title":"Ann Intern Med"},{"key":"1386_CR2","doi-asserted-by":"publisher","first-page":"e000435","DOI":"10.1136\/rmdopen-2017-000435","volume":"3","author":"C Heijl","year":"2017","unstructured":"Heijl\u00a0C, Mohammad\u00a0AJ, Westman\u00a0K et al (2017) Long-term patient survival in a\u00a0Swedish population-based cohort of patients with ANCA-associated vasculitis. RMD Open 3:e435","journal-title":"RMD Open"},{"key":"1386_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette\u00a0JC, Falk\u00a0RJ, Bacon\u00a0PA et\u00a0al (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1\u201311","journal-title":"Arthritis Rheum"},{"key":"1386_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/art.30286","volume":"63","author":"RJ Falk","year":"2011","unstructured":"Falk\u00a0RJ, Gross\u00a0WL, Guillevin\u00a0L et\u00a0al (2011) Granulomatosis with polyangiitis (Wegener\u2019s): an alternative name for Wegener\u2019s granulomatosis. Arthritis Rheum 63:863\u2013864","journal-title":"Arthritis Rheum"},{"key":"1386_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJMoa1108735","volume":"367","author":"PA Lyons","year":"2012","unstructured":"Lyons\u00a0PA, Rayner\u00a0TF, Trivedi\u00a0S et al (2012) Genetically distinct subsets within ANCA-associated vasculitis. N\u00a0Engl J Med 367:214\u2013223","journal-title":"N Engl J Med"},{"key":"1386_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.ajkd.2019.04.031","volume":"75","author":"D Geetha","year":"2020","unstructured":"Geetha\u00a0D, Jefferson\u00a0JA (2020) ANCA-associated vasculitis: core curriculum 2020. Am J Kidney Dis 75:124\u2013137","journal-title":"Am J Kidney Dis"},{"key":"1386_CR7","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1136\/ard.2010.130203","volume":"69","author":"JU Holle","year":"2010","unstructured":"Holle\u00a0JU, Gross\u00a0WL, Holl-Ulrich\u00a0K et al (2010) Prospective long-term follow-up of patients with localised Wegener\u2019s granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis 69:1934\u20131939","journal-title":"Ann Rheum Dis"},{"key":"1386_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","volume":"72","author":"F Moosig","year":"2013","unstructured":"Moosig\u00a0F, Bremer\u00a0JP, Hellmich\u00a0B et al (2013) A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150\u00a0patients. Ann Rheum Dis 72:1011\u20131017","journal-title":"Ann Rheum Dis"},{"key":"1386_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/art.37721","volume":"65","author":"C Comarmond","year":"2013","unstructured":"Comarmond\u00a0C, Pagnoux\u00a0C, Khellaf\u00a0M et al (2013) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383\u00a0patients enrolled in the French vasculitis study group cohort. Arthritis Rheum 65:270\u2013281","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1386_CR10","first-page":"309","volume":"81","author":"JC Robson","year":"2022","unstructured":"Robson\u00a0JC, Grayson\u00a0PC, Ponte\u00a0C et\u00a0al (2022) 2022 American college of rheumatology\/European alliance of associations for rheumatology classification criteria for granulomatosis with polyangiitis. Arthritis Rheumatol 81(3):309\u2013314","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1386_CR11","first-page":"309","volume":"81","author":"PC Grayson","year":"2022","unstructured":"Grayson\u00a0PC, Ponte\u00a0C, Suppiah\u00a0R et\u00a0al (2022) 2022 American college of rheumatology\/European alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Arthritis Rheumatol 81(3):309\u2013314","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1386_CR12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/art.41983","volume":"74","author":"R Suppiah","year":"2022","unstructured":"Suppiah\u00a0R, Robson\u00a0JC, Grayson\u00a0PC et\u00a0al (2022) 2022 American college of rheumatology\/European alliance of associations for rheumatology classification criteria for microscopic polyangiitis. Arthritis Rheumatol 74(3):400\u2013406. https:\/\/doi.org\/10.1002\/art.41983","journal-title":"Arthritis Rheumatol"},{"key":"1386_CR13","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1093\/rheumatology\/kez597","volume":"59","author":"AT Nilsen","year":"2020","unstructured":"Nilsen\u00a0AT, Karlsen\u00a0C, Bakland\u00a0G et al (2020) Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway. Rheumatology (Oxford) 59:2316\u20132324","journal-title":"Rheumatology (Oxford)"},{"key":"1386_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/rheumatology\/kev286","volume":"55","author":"JH Schirmer","year":"2016","unstructured":"Schirmer\u00a0JH, Wright\u00a0MN, Vonthein\u00a0R et al (2016) Clinical presentation and long-term outcome of 144\u00a0patients with microscopic polyangiitis in a\u00a0monocentric German cohort. Rheumatology (Oxford) 55:71\u201379","journal-title":"Rheumatology (Oxford)"},{"key":"1386_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/art.27763","volume":"63","author":"JU Holle","year":"2011","unstructured":"Holle\u00a0JU, Gross\u00a0WL, Latza\u00a0U et\u00a0al (2011) Improved outcome in 445\u00a0patients with Wegener\u2019s granulomatosis in a\u00a0German vasculitis center over four decades. Arthritis Rheum 63:257\u2013266","journal-title":"Arthritis Rheum"},{"key":"1386_CR16","first-page":"355","volume":"105","author":"K Herlyn","year":"2008","unstructured":"Herlyn\u00a0K, Hellmich\u00a0B, Gross\u00a0WL et al (2008) Stable incidence of systemic vasculitides in Schleswig-Holstein, Germany. Dtsch Arztebl Int 105:355\u2013361","journal-title":"Dtsch Arztebl Int"},{"key":"1386_CR17","first-page":"589","volume":"56","author":"FA Pearce","year":"2017","unstructured":"Pearce\u00a0FA, Grainge\u00a0MJ, Lanyon\u00a0PC et\u00a0al (2017) The incidence, prevalence and mortality of granulomatosis with polyangiitis in the UK clinical practice research datalink. Rheumatology (Oxford) 56:589\u2013596","journal-title":"Rheumatology (Oxford)"},{"key":"1386_CR18","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1055\/s-0043-101977","volume":"142","author":"M Krasselt","year":"2017","unstructured":"Krasselt\u00a0M, Pierer\u00a0M, Amann\u00a0K et al (2017) Clinical course of an early childhood-onset granulomatosis with polyangiitis. Dtsch Med Wochenschr 142:904\u2013908","journal-title":"Dtsch Med Wochenschr"},{"key":"1386_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/ard.2006.062711","volume":"66","author":"B Hellmich","year":"2007","unstructured":"Hellmich\u00a0B, Flossmann\u00a0O, Gross\u00a0WL et al (2007) EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66:605\u2013617","journal-title":"Ann Rheum Dis"},{"key":"1386_CR20","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/rheumatology\/kes382","volume":"52","author":"JU Holle","year":"2013","unstructured":"Holle\u00a0JU, Voigt\u00a0C, Both\u00a0M et\u00a0al (2013) Orbital masses in granulomatosis with polyangiitis are associated with a\u00a0refractory course and a\u00a0high burden of local damage. Rheumatology (Oxford) 52:875\u2013882","journal-title":"Rheumatology (Oxford)"},{"key":"1386_CR21","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1093\/rheumatology\/kez071","volume":"58","author":"CA Durel","year":"2019","unstructured":"Durel\u00a0CA, Hot\u00a0A, Trefond\u00a0L et al (2019) Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59\u00a0patients. Rheumatology (Oxford) 58:1565\u20131573","journal-title":"Rheumatology (Oxford)"},{"key":"1386_CR22","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1093\/rheumatology\/ker236","volume":"50","author":"N Arulkumaran","year":"2011","unstructured":"Arulkumaran\u00a0N, Periselneris\u00a0N, Gaskin\u00a0G et al (2011) Interstitial lung disease and ANCA-associated vasculitis: a\u00a0retrospective observational cohort study. Rheumatology (Oxford) 50:2035\u20132043","journal-title":"Rheumatology (Oxford)"},{"key":"1386_CR23","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-019-12515-9","volume":"10","author":"PA Lyons","year":"2019","unstructured":"Lyons\u00a0PA, Peters\u00a0JE, Alberici\u00a0F et al (2019) Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun 10:5120","journal-title":"Nat Commun"},{"key":"1386_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00393-017-0394-1","volume":"76","author":"JH Schirmer","year":"2017","unstructured":"Schirmer\u00a0JH, Aries\u00a0PM, de Groot\u00a0K et al (2017) S1 guidelines diagnostics and treatment of ANCA-associated vasculitis. Z\u00a0Rheumatol 76:77\u2013104","journal-title":"Z Rheumatol"},{"key":"1386_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","volume":"15","author":"D Nakazawa","year":"2019","unstructured":"Nakazawa\u00a0D, Masuda\u00a0S, Tomaru\u00a0U et al (2019) Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 15:91\u2013101","journal-title":"Nat Rev Rheumatol"},{"key":"1386_CR26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","volume":"13","author":"X Bossuyt","year":"2017","unstructured":"Bossuyt\u00a0X, Cohen Tervaert\u00a0JW, Arimura\u00a0Y et\u00a0al (2017) Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 13:683\u2013692","journal-title":"Nat Rev Rheumatol"},{"key":"1386_CR27","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates\u00a0M, Watts\u00a0RA, Bajema\u00a0IM et al (2016) EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583\u20131594","journal-title":"Ann Rheum Dis"},{"key":"1386_CR28","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/acr.24634","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung\u00a0SA, Langford\u00a0CA, Maz\u00a0M et al (2021) 2021 American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken) 73:1088\u20131105","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1386_CR29","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh\u00a0M, Merkel\u00a0PA, Peh\u00a0CA et al (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N\u00a0Engl J Med 382:622\u2013631","journal-title":"N Engl J Med"},{"key":"1386_CR30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne\u00a0DRW, Merkel\u00a0PA, Schall\u00a0TJ et al (2021) Avacopan for the treatment of ANCA-associated vasculitis. N\u00a0Engl J Med 384:599\u2013609","journal-title":"N Engl J Med"},{"key":"1386_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2013020143","volume":"25","author":"H Xiao","year":"2014","unstructured":"Xiao\u00a0H, Dairaghi\u00a0DJ, Powers\u00a0JP et al (2014) C5a receptor (CD88) blockade protects against MPO-ANCA GN. J\u00a0Am Soc Nephrol 25:225\u2013231","journal-title":"J Am Soc Nephrol"},{"key":"1386_CR32","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.6408095","author":"B Terrier","year":"2021","unstructured":"Terrier\u00a0B, Pugnet\u00a0G, de Moreuil\u00a0C et al (2021) Rituximab versus conventional therapeutic strategy for remission induction in eosinophilic granulomatosis with polyangiitis: a double-blind, randomized, controlled trial. Arthritis Rheumatol. https:\/\/doi.org\/10.5281\/zenodo.6408095","journal-title":"Arthritis Rheumatol"},{"key":"1386_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone\u00a0JH, Merkel\u00a0PA, Spiera\u00a0R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N\u00a0Engl J Med 363:221\u2013232","journal-title":"N Engl J Med"},{"key":"1386_CR34","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","volume":"18","author":"DR Jayne","year":"2007","unstructured":"Jayne\u00a0DR, Gaskin\u00a0G, Rasmussen\u00a0N et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J\u00a0Am Soc Nephrol 18:2180\u20132188","journal-title":"J Am Soc Nephrol"},{"key":"1386_CR35","doi-asserted-by":"publisher","first-page":"e064604","DOI":"10.1136\/bmj-2021-064604","volume":"376","author":"M Walsh","year":"2022","unstructured":"Walsh\u00a0M, Collister\u00a0D, Zeng\u00a0L et al (2022) The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ 376:e64604","journal-title":"BMJ"},{"key":"1386_CR36","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler\u00a0ME, Akuthota\u00a0P, Jayne\u00a0D et\u00a0al (2017) Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N\u00a0Engl J Med 376:1921\u20131932","journal-title":"N Engl J Med"},{"issue":"SI2","key":"1386_CR37","doi-asserted-by":"publisher","first-page":"SI180","DOI":"10.1093\/rheumatology\/keac089","volume":"61","author":"M Krasselt","year":"2022","unstructured":"Krasselt\u00a0M, Wagner\u00a0U, Nguyen\u00a0P et al (2022) Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions. Rheumatology (Oxford) 61(SI2):SI180\u2013SI188","journal-title":"Rheumatology (Oxford)"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01386-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-022-01386-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01386-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T10:03:53Z","timestamp":1661249033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-022-01386-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1386"],"URL":"https:\/\/doi.org\/10.1007\/s00108-022-01386-w","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]},"assertion":[{"value":"5 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>M.\u00a0Krasselt<\/b>: A.\u00a0Finanzielle Interessen: Patente, Gesch\u00e4ftsanteile, Aktien o.\u202f\u00c4. an einer im Medizinbereich aktiven Firma: Aktienanteile von AbbVie, Johnson & Johnson, Pfizer und BioNTech. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Angestellter Internist und Rheumatologe, Universit\u00e4tsklinikum Leipzig A\u00f6R, Medizinische Klinik\u00a0III\u00a0\u2013 Endokrinologie, Nephrologie und Rheumatologie | Mitgliedschaften: DGRh; DGIM; Mitglied und Koordinationsarzt, Rheumazentrum Leipzig e.\u202fV. <b>J.\u00a0Holle<\/b>: A.\u00a0Finanzielle Interessen: Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Anmerkung: keine Pharma-gesponserten Vortr\u00e4ge im Zusammenhang mit ANCA-assoziierten Vaskulitiden (AAV) in den letzten 5\u00a0Jahren aus Gr\u00fcnden der Mitgliedschaft in der Kommission Pharmakotherapie der Deutschen Gesellschaft f\u00fcr Rheumatologie (DGRh); Mitarbeit an diversen Leitlinien (deutsch, europ\u00e4isch). \u2013\u00a0Patente, Gesch\u00e4ftsanteile, Aktien o.\u202f\u00c4. an einer im Medizinbereich aktiven Firma: Carl Zeiss Meditec, 39\u00a0St\u00fcck; Eckert + Ziegler, 40\u00a0St\u00fcck; Merck KGaA, 24\u00a0St\u00fcck; Siemens Health, 17\u00a0St\u00fcck; BioNTech, 39\u00a0St\u00fcck; CureVac, 162 St\u00fcck.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Niedergelassene \u00c4rztin und gesch\u00e4ftsf\u00fchrende Gesellschafterin Rheumazentrum Schleswig-Holstein Mitte GbR in Kiel und Neum\u00fcnster; au\u00dferplanm\u00e4\u00dfige Professur\/Lehre an der Medizinischen Universit\u00e4t zu L\u00fcbeck | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Innere Medizin (DGIM), DGRh, Deutsche Gesellschaft f\u00fcr Immunologie (DGfI), Berufsverband Deutscher Rheumatologen (BDRh), European Vasculitis Society (EUVAS); Kommissionsarbeit: Ad-Hoc-Kommission COVID-19 der DGRh, Kommission Pharmakotherapie der DGRh (stellv. Sprecherin); aktuelle Arbeit an Leitlinien: Koordinatorin der S3-Leitlinie Update AAV der DGRh\/Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Mitglied der EUVAS-Gruppe Update der \u201eEULAR recommendations for the management of AAV\u201c.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}